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Background: The primary objective of this study was to determine
the incidence of symptomatic venous thromboembolism (VTE),
including pulmonary embolism (PE) and deep vein thrombosis
(DVT), in the hip fracture population. Secondary objectives included
determining timing of VTE diagnosis, VTE thromboprophylaxis
given, and identifying any factors associated with VTE.
Methods: Using data from the FAITH and HEALTH trials, the
incidence of VTE, including DVT and PE, and the timing of VTE
were determined. A multivariable Cox regression analysis was used
to determine which factors were associated with increased risk of
VTE, including age, treatment for comorbidity, thromboprophylaxis,
time to surgery, and method of fracture management.
Results: 2520 hip fracture patients were included in the analysis.
Sixty-four patients (2.5%) had a VTE [DVT: 36 (1.4%), PE: 28
(1.1%)]. Thirty-five (54.7%) were diagnosed less than 6 weeks
postfracture and 29 (45.3%) more than 6 weeks postfracture. One
thousand nine hundred ninety-three (79%) patients received throm-
boprophylaxis preoperatively and 2502 (99%) received thrombopro-
phylaxis postoperatively. The most common method of preoperative
(46%) and postoperative (73%) thromboprophylaxis was low
molecular weight heparin. Treatment with arthroplasty compared
to internal fixation was the only variable associated with increased
risk of VTE (hazard ratio 2.67, P = 0.02).
Conclusions: The incidence of symptomatic VTE in hip fracture
patients recruited to the 2 trials was 2.5%. Although over half of the
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cases were diagnosed within 6 weeks of fracture, VTE is still
prevalent after this period. The majority of patients received
thromboprophylaxis. Treatment with arthroplasty rather than fixation
was associated with increased incidence of VTE.
Key Words: femoral neck fracture, venous thromboembolism, pul-
monary embolism, deep vein thrombosis
Level of Evidence: Therapeutic Level II. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:S70–S75)
INTRODUCTION
Venous thromboembolism (VTE), which comprises
deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a common cause of morbidity and mortality in hip
fracture patients.1 Although most cases are asymptomatic, in
the absence of thromboprophylaxis, postoperative VTE rates
of up to 80% have been reported.2 Symptomatic VTE is less
common, particularly when thromboprophylaxis is used. In
the presence of thromboprophylaxis, the incidence of symp-
tomatic postoperative DVT and PE has been reported from
1.18%–6% and 0.25%–4.6%, respectively.3–6
Symptomatic VTE is most often diagnosed within the
first 30 days after hip fracture,7,8 but patients may be at
increased risk for up to 1 year after surgery.9 VTE is also
commonly present before surgery in hip fracture patients,
although this is usually asymptomatic.10–12 A number of
factors have been associated with an increased risk of
VTE in hip fracture patients including delay to surgery,
extracapsular fracture pattern, and pulmonary disease.8,10,13
The increased risk of VTE after hip fracture is well recog-
nized and VTE prevention is emphasized by many organi-
zations including the National Institute for Health and
Clinical Excellence (NICE),14 the Scottish Intercollegiate
Guidelines Network, and American College of Chest
Physicians.14–16 These bodies recommend different combi-
nations of chemical and mechanical VTE prophylaxis, but
all agree that VTE prophylaxis should be instituted for hip
fracture patients.
Analyses of the data from the FAITH (Fixation using
Alternative Implants for the Treatment of Hip fractures) and
the HEALTH (Hip fracture evaluations with Alternatives of
Total Hip Arthroplasty vs. Hemiarthroplasty) trials both
independently and combined were performed.17,18 The pri-
mary objective was to determine the incidence of symp-
tomatic VTE, including DVT and PE, in the population
of hip fracture patients included in these studies.
Secondary objectives were to determine the timing of
VTE diagnosis, determine the proportion of patients receiv-
ing VTE prophylaxis and the type of prophylaxis given,
describe the differences in patients who suffered a VTE
and those who did not, and to determine which factors were
associated with VTE.
METHODS
In this preplanned study, we analyzed the data from the
1079-patient FAITH and the 1441-patient HEALTH trials to
determine the incidence of symptomatic VTE, including DVT
and PE, in this population of 2520 hip fracture patients. In
both studies, incidence of symptomatic VTE was recorded as
a secondary outcome during inpatient stay and when
participants returned for follow-up (either in person or
through telephone) at 1 and 10 weeks, and at 6, 9, 12, 18,
and 24 months after surgery. This allowed for both incidence
of VTE in this population and the timing of VTE diagnosis to
be determined and presented as frequencies and percentages.
In both studies, the baseline characteristics of all
patients included were recorded, including age, sex, body
mass index, prefracture living setting, prefracture functional
status, American Society of Anesthesiologists (ASA) classi-
fication, and comorbidity. This allowed us to describe the
characteristics of patients who suffered a VTE and the
characteristics of patients who did not. The preoperative
and postoperative VTE prophylaxis given for each patient
was also recorded, allowing us to determine the proportion of
patients receiving VTE prophylaxis and the type of VTE
prophylaxis given. Method of fracture management and time
from injury to surgery were also recorded in each trial. We
used descriptive statistics to summarize these results (fre-
quencies and percentages for categorical variables and means
and ranges for continuous variables).
A multivariable Cox regression analysis was used to
determine which factors were associated with increased risk
of symptomatic VTE including: age, treatment for comorbid-
ity (yes vs. no), thromboprophylaxis (medical vs. nonmedi-
cal), time from injury to surgery, and method of fracture
management (arthroplasty vs. internal fixation). Factors were
selected based on biological rationale, previous literature, and
expert opinion. Statistical analysis was conducted using R
(version 3.6.1, R Foundation for Statistical Computing,
Vienna, Austria). Results were presented as hazard ratios
(HRs), 95% confidence intervals (CIs), and P-values. A P-
value of less than 0.05 was considered to be statistically
significant.
RESULTS
In the FAITH trial, 1079 patients were randomized to
treatment. At 24 months, 923 patients were alive, and
complete follow-up was achieved for 844 (91%).17 In the
HEALTH trial, 1441 patients were randomized to treat-
ment.18 At 24 months, 1243 patients were alive, and complete
follow-up was achieved for 1058 (85.1%).
Within the FAITH trial, 17 cases of VTE were recorded
(1.6%) and 47 cases of VTE were recorded within the
HEALTH trial (3.3%), resulting in a total of 64 cases of
symptomatic VTE across the 2520 hip fracture patients from
both studies and an incidence of VTE of 2.5%. The baseline
characteristics of patients who suffered a VTE and those who
did not suffer a VTE are summarized in Table 1.
In the FAITH trial, 12 cases of DVT were recorded
(1.1%) with 24 cases of DVT in the HEALTH trial (1.7%). In
total, 36 cases of symptomatic DVT were recorded across the
2520 hip fracture patients from both studies giving an
incidence of symptomatic DVT of 1.4%. The FAITH trial
recorded 5 cases of PE (0.5%) and 23 cases of PE were
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recorded in the HEALTH trial (1.6%). A total of 28 cases of
PE were recorded across the 2520 hip fracture patients from
both studies giving an incidence of PE of 1.1%.
The timing of VTE diagnosis is summarized in Table 2.
Across both studies, 3 (4.7%) cases of VTE were diagnosed
presurgery and 61 (95.3%) were diagnosed postsurgery. Of
VTE cases, 22 (34.4%) were diagnosed prehospital discharge
and 42 (65.6%) were diagnosed posthospital discharge.
Overall, 35 (54.7%) cases of VTE were diagnosed less than
6 weeks postfracture and 29 (45.3%) were diagnosed more
than 6 weeks postfracture.
The proportion of patients given VTE prophylaxis
and the type of prophylaxis used are summarized in
Table 3. Across both studies, 1993 patients (79.3%)
received thromboprophylaxis preoperatively and 2502
(99.4%) received thromboprophylaxis postoperatively.
The most common methods of preoperative thrombopro-
phylaxis were low molecular weight heparin (LMWH)
(46.0%) and mechanical prophylaxis (18.0%). The most
common method of postoperative thromboprophylaxis
was LMWH (73.0%).
The results of the multivariable Cox regression analysis
are summarized in Table 4. Advancing age, receiving treat-
ment for a comorbidity, type of postoperative thrombopro-
phylaxis, and increased time from injury to surgery were
not associated with an increased incidence of symptomatic
VTE (P . 0.05). However, surgical treatment with arthro-
plasty was associated with an increased incidence of symp-
tomatic VTE within 24 months of hip fracture compared to
surgical treatment with internal fixation (HR 2.21, P = 0.02).
Total hip arthroplasty and hemiarthroplasty versus internal
TABLE 1. Characteristics of Patients Who had a VTE
Variable No VTE, N = 2456 VTE, N = 64
Age, mean (SD) 75.7 (10.8) 77.3 (10.0)
Sex, n (%)
Male 829 (33.9) 24 (37.5)
Female 1617 (66.1) 40 (62.5)
Body mass index, mean (SD) 24.8 (4.7) 25.4 (5.0)
Prefracture living setting, n (%)
Institutionalized 116 (4.7) 2 (3.1)
Not institutionalized 2340 (95.3) 62 (96.9)
Prefracture functional status, n (%)
Use of aid 581 (23.7) 19 (29.7)
Independent ambulator 1875 (76.3) 45 (70.3)
ASA classification, n (%)
Class I/II 1302 (53.0) 34 (53.1)
Class III/IV/V 1154 (47.0) 30 (46.9)
Receiving treatment for major
comorbidities, n (%)
Osteopenia 34 (1.4) 0 (0.0)
Osteoporosis 129 (5.3) 9 (14.1)
Lung disease 316 (12.9) 7 (10.9)
Diabetes 328 (13.4) 10 (15.6)
Ulcers or stomach disease 213 (8.7) 8 (12.5)
Kidney disease 112 (4.6) 5 (7.8)
Anemia or other blood disease 109 (4.4) 6 (9.4)
Depression 259 (10.6) 5 (7.8)
Cancer 117 (4.8) 4 (6.3)
Osteoarthritis, degenerative
arthritis
204 (8.3) 3 (4.7)
Back pain 178 (7.3) 3 (4.7)
Rheumatoid arthritis 47 (1.9) 6 (9.4)
Heart disease 644 (26.2) 11 (17.2)
High blood pressure 1192 (48.5) 31 (48.4)
Method of fracture management, n
(%)
Internal fixation 1062 (43.2) 17 (26.6)




Heparin 143 (5.8) 2 (3.1)
Warfarin 68 (2.8) 0 (0.0)
DOAC/other oral 47 (1.9) 1 (1.6)
acetylsalicylic acid 16 (0.7) 0 (0.0)
LMWH 1120 (45.6) 32 (50.0)
Mechanical only 433 (17.6) 9 (14.1)
Medical and mechanical
Heparin and mechanical 23 (0.9) 0 (0.0)
Warfarin and mechanical 10 (0.4) 1 (1.6)
DOAC/other oral and
mechanical
3 (0.1) 0 (0.0)
acetylsalicylic acid and
mechanical
2 (0.1) 0 (0.0)
LMWH and mechanical 67 (2.7) 1 (2.9)
None 509 (20.7) 18 (28.1)
Postoperative thromboprophylaxis,
n (%)*
TABLE 1. (Continued ) Characteristics of Patients Who had a
VTE
Variable No VTE, N = 2456 VTE, N = 64
Medical only
Heparin 158 (6.4) 3 (4.7)
Warfarin 95 (3.9) 2 (3.1)
DOAC/other oral 91 (3.7) 3 (4.7)
acetylsalicylic acid 25 (1.0) 0 (0.0)
LMWH 1804 (73.5) 51 (79.7)
Mechanical only 81 (3.3) 0 (0.0)
Medical and mechanical
Heparin and mechanical 25 (1.0) 0 (0.0)
Warfarin and mechanical 37 (1.5) 1 (1.6)
DOAC/other oral and
mechanical
13 (0.5) 0 (0.0)
acetylsalicylic acid and
mechanical
23 (0.9) 0 (0.0)
LMWH and mechanical 175 (7.1) 6 (9.4)
None 14 (0.6) 0 (0.0)
Time from injury to surgery, mean
(SD) (hours)
52.0 (75.6) 40.1 (31.8)
*In some cases, more than one type of thromboprophylaxis was used.
ASA, American Society of Anesthesiologists; DOAC, direct oral anticoagulants;
LMWH, low-molecular-weight heparin; SD, standard deviation; VTE, venous throm-
boembolism.
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fixation were associated with a 2.67 and 1.77 times increase
in VTE, respectively.
DISCUSSION
This sub-analysis of data from the FAITH and
HEALTH trials demonstrates that the incidence of symp-
tomatic VTE in hip fracture patients included in these trials
is 2.5%, with the overall combined incidence of symptom-
atic DVT being 1.4%. The FAITH trial recorded 5 cases of
PE (0.5%) and 23 cases of PE were recorded in the
HEALTH trial (1.6%). Although over half of cases were
diagnosed within 6 weeks of the fracture, VTE is still
prevalent after this period. The majority of patients received
thromboprophylaxis before and after surgery with LMWH
given alone being the most common type of VTE
TABLE 2. Timing of VTE in FAITH and HEALTH
Weeks From Hip Fracture FAITH, N = 17 HEALTH, N = 47 Overall, N = 64
Presurgery, n (%) 0 (0.0) 3 (6.4) 3 (4.7)
Postsurgery, n (%) 17 (100.0) 44 (93.6) 61 (95.3)
Prehospital discharge, n (%) 3 (17.6) 19 (40.4) 22 (34.4)
Posthospital discharge, n (%) 14 (82.4) 28 (59.6) 42 (65.6)
,6 wk postfracture, n (%) 8 (47.0) 27 (57.5) 35 (54.7)
$6 wk postfracture, n (%) 9 (53.0) 20 (42.5) 29 (45.3)
TABLE 3. VTE Prophylaxis in FAITH and HEALTH




Heparin 73 (6.8) 72 (5.0) 145 (5.7)
Warfarin 37 (3.4) 31 (2.2) 68 (2.7)
DOAC/other oral 29 (2.7) 21 (1.5) 50 (2.0)
ASA 3 (0.3) 10 (0.7) 13 (0.5)
LMWH 506 (46.9) 663 (46.0) 1169 (46.0)
Mechanical only 280 (25.9) 177 (12.3) 457 (18.0)
Medical and mechanical
Heparin and mechanical 16 (1.5) 7 (0.5) 23 (0.9)
Warfarin and mechanical 5 (0.5) 6 (0.4) 11 (0.4)
DOAC/other oral and 2 (0.2) 1 (0.1) 3 (0.1)
Mechanical
ASA and mechanical 0 (0.0) 2 (0.2) 0 (0.0)
LMWH and mechanical 41 (3.8) 27 (1.9) 2 (0.1)




Heparin 85 (7.9) 76 (5.3) 161 (6.3)
Warfarin 39 (3.6) 58 (4.0) 97 (3.8)
DOAC/other oral 52 (4.8) 29 (2.0) 81 (3.2)
ASA 11 (1.0) 14 (1.0) 25 (1.0)
LMWH 733 (67.9) 1122 (77.9) 1855 (73.0)
Mechanical only 40 (3.7) 41 (2.9) 81 (3.2)
Medical and mechanical
Heparin and mechanical 18 (1.7) 7 (0.5) 25 (1.0)
Warfarin and mechanical 10 (0.9) 28 (1.9) 38 (1.5)
DOAC/other oral and
mechanical
6 (0.6) 7 (0.5) 13 (0.5)
ASA and mechanical 6 (0.6) 17 (1.2) 23 (0.9)
LMWH and mechanical 120 (11.1) 61 (4.2) 181 (7.2)
None 5 (0.5) 9 (0.6) 14 (0.6)
*In some cases, more than one type of thromboprophylaxis was used.
ASA, acetylsalicylic acid; DOAC, direct oral anticoagulants; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
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prophylaxis given preoperatively and postoperatively.
Treatment with arthroplasty rather than fixation was the
only factor analyzed that was associated with increased
incidence of symptomatic VTE in this population.
The incidence of symptomatic VTE from the FAITH
and HEALTH trials is comparable to the incidences reported
in other large studies. The ESCORTE study was a multicenter
cohort study of 6860 hip fracture patients, 98% of whom
received VTE prophylaxis with LMWH.5 The authors re-
ported a VTE incidence of 1.34% at 3 months of follow-up,
with a 1.09% incidence of DVT and 0.25% incidence of PE.
The Pulmonary Embolism Prevention trial was a multicenter
randomized controlled trial comparing VTE thromboprophy-
laxis with aspirin or placebo, in addition to other thrombo-
prophylaxis thought necessary in hip fracture patients.3 In the
6679 patients assigned aspirin, the authors reported a VTE
incidence of 1.6% at 35 days of follow-up, with a 1% inci-
dence of DVT and 0.7% incidence of PE. McNamara et al8
conducted a single-center cohort study of 5300 hip fracture
patients, all of whom received thromboprophylaxis with hep-
arin. The authors reported a 2.2% incidence of symptomatic
VTE at 1-year follow-up, with a 1.5% incidence of DVT and
0.7% incidence of PE.
Although the majority (55%) of symptomatic VTE
occurred within 6 weeks of hip fracture in the current study,
a significant percentage occurred after this period. This is in
keeping with the results of other large studies. Bjørnara ̊ et al
conducted a single-center cohort study of 2420 hip fracture
patients with 6 months of follow-up.7 Thirty-six patients had
a symptomatic DVT. The median time to diagnosis was 24
days (range 3–150 days). Thirty-nine patients had a symp-
tomatic PE. The median time to diagnosis was 17 days
(range 1–173 days). McNamara et al8 reported a mean time
to VTE presentation of 24 days (range 3–91 days). Mean
time to DVT presentation was 25 days (range 4–91 days)
and mean time to PE presentation was 20 days (range 3–81
days). Eighty-five percent of VTE events occurred within 5
weeks of fracture, but patients presented up to 13 weeks
after the injury. Despite the majority of cases presenting
within the first 6 weeks in the current study, VTE was still
prevalent after this period with 45% of cases presenting after
6 weeks. Pedersen et al9 conducted a cohort study from the
Danish Health registry comparing 110,563 hip fracture
patients to a cohort of 552,774 people from the general
population.bib9 The adjusted HR of VTE among hip frac-
ture patients was highest during the first 30 days after hip
fracture (HR = 17.29, 95% CI: 14.74–20.28), but remained
elevated during 31–365 days after hip fracture (HR = 2.13,
95% CI: 1.95–2.32). Although this prolonged increased risk
of VTE is consistent with this current study, our results
suggest that risk may be greater than previously
demonstrated.
National Institute for Health and Clinical Excellence
(NICE, UK), Scottish Intercollegiate Guidelines Network,
and American College of Chest Physicians guidance docu-
ments recommend preoperative medical VTE prophylaxis
with heparin unless contraindication exists, in addition to
preoperative mechanical VTE prophylaxis for patients with
hip fractures.14–16 These guidelines also recommend postop-
erative VTE prophylaxis with heparin, unless contraindica-
tion exists, in addition to mechanical VTE prophylaxis until
the patient’s mobility is no longer significantly reduced. In
our subanalysis, 61.3% of patients received preoperative med-
ical thromboprophylaxis, most commonly with LMWH
(46.1%), and 23.1% of patients received preoperative
mechanical prophylaxis. 96.2% of patients received medical
VTE prophylaxis postoperatively, most commonly with
LMWH (80.2%), and 11% received postoperative mechanical
prophylaxis. The lower rate of preoperative medical VTE
prophylaxis may be partially due to early surgery preventing
the use of anticoagulants, but our study suggests that mechan-
ical VTE prophylaxis is often not used preoperatively or post-
operatively despite advice from available guidelines. The use
of mechanical VTE prophylaxis has been suggested to confer
additional benefit when used with medical prophylaxis and
this is an area of practice that may be improved.19
Regression analysis in this study demonstrated that age
was not associated with VTE incidence. This is consistent
with analyses performed by McNamara et al and the
ESCORTE study, both of which showed that age was not
associated with postoperative symptomatic VTE.5,8 In addi-
tion, a regression analysis by Shin et al11 demonstrated that
age was not associated with preoperative DVT diagnosed by
multidetector CT venography. Our analysis also demonstrated
that patient comorbidity was not associated with VTE inci-
dence. The analysis by Shin et al also showed that many
comorbidities including diabetes, hypertension, and cardiac
disease were not associated with VTE, but suggested that
pulmonary disease was associated with increased risk of
VTE. Our analysis demonstrated that time from injury to
surgery was not associated with increased risk of VTE.
Although there is limited evidence investigating the effect
of time to surgery on postoperative VTE, several studies have
suggested that delay increases the risk of preoperative
VTE.10,20
TABLE 4. Association Between Thromboprophylaxis and VTE
Incidence Post Internal Fixation or Arthroplasty Surgery (N =
2,231, 56 Events)*
Variable HR (95% CI) P
Age (y) 0.99 (0.97–1.03) 0.94
Receiving treatment for a
comorbidity yes vs. no
1.46 (0.76–2.78) 0.25
Postoperative thromboprophylaxis
medical vs. not medical
1.27 (0.54–2.97) 0.58
Time from injury to surgery (h) 0.99 (0.986–1.002) 0.11
Method of fracture management
arthroplasty vs. internal fixation
2.21 (1.15–4.26) 0.02
Method of fracture management






*Patients with VTE occurring before the initial surgery were excluded from this analysis.
CI, confidence interval; HR, hazard ratio; OR, odds ratio.
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Our regression analysis demonstrated that treatment
with arthroplasty as opposed to fixation was associated with
an over 2-fold increased incidence of VTE, and that this
increased risk was greater with total hip arthroplasty than
hemiarthroplasty. No published studies have previously
compared VTE incidence for arthroplasty and fixation as
surgical treatments for a femoral neck fracture. Analyses by
McNamara et al. and Shin et al demonstrated that intertro-
chanteric and subtrochanteric fracture patterns were associ-
ated with increased incidence of postoperative VTE compared
to femoral neck fractures.8,11 Although this may suggest that
fixation increases postoperative VTE incidence, these studies
are not directly comparable to our study of femoral neck
fractures only.
The main strength of our subanalysis is that our data are
sourced from 2 large-scale international studies, which both
had broad inclusion criteria with recruitment from a large
number of hospitals in diverse health care systems. These
results are therefore more likely to give a realistic picture of
symptomatic VTE in hip fracture patients. Although the use
of imaging to screen patients may identify many more cases
of VTE, our study used symptomatic VTE as its outcome,
which we believe makes our results more clinically relevant
to patients and current practice in most health care systems.
A limitation of our subanalysis is the loss of patients
over the 24 months of follow-up in both studies. However,
the loss to follow-up in both studies was consistent with or
better than other trials including hip fracture patients.21 Both
studies also had unavoidable heterogeneity of variables such
as patient positioning, surgical exposure, use of traction, type
of anesthetic and physiotherapy and rehabilitation protocols,
which may have affected results.
In conclusion, the incidence of symptomatic VTE in the
hip fracture patients recruited to the FAITH and HEALTH
trials was 2.5%. Although over half of cases were diagnosed
within 6 weeks of surgery, VTE was still prevalent after this
period with 45% of patients presenting after 6 weeks. The
majority of patients received thromboprophylaxis before and
after surgery, but mechanical prophylaxis was not commonly
used. Although several factors were examined, only treatment
with arthroplasty rather than fixation was associated with
increased incidence of VTE.
The high incidence of symptomatic VTE over 6 weeks
after surgery and the increased VTE risk with arthroplasty
seen in our study have not been previously described. These
results should be considered to guide future clinical decision
making in hip fracture patients.
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